Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Although many intratympanic agents have been attempted, N-Acetylcysteine (NAC) appears to be
the most promising and is a powerful, commonly used anti-oxidant. The goal of this
prospective phase 2 randomized controlled trial is to determine the optimal dosage and
effectiveness of intratympanic NAC injection in reducing hearing loss in head & neck cancer
patients receiving cisplatin chemotherapy with curative intent.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborators:
London Regional Cancer Program, Canada Toronto Sunnybrook Regional Cancer Centre